International Journal of Endocrinology and Metabolism
Research Institute for Endocrine Sciences
Scopus by Title (Ref)
1. SGLT2-inhibition and myocardial infarction size in patients with type 2 diabetes mellitus– Insights from an acute cardiovascular care center
- Bojti I. , et al.
2. ADD2Dia: Real-World Clinical Effectiveness of Adding a Sodium-Glucose Cotransporter 2 Inhibitor to Gliclazide-Based Therapy in Type 2 Diabetes
- Moreira R.O. , et al.
3. SGLT2 inhibitors reduce the risk of renal failure in CKD stage 5 patients with Type 2 DM
- Huang B. , et al.
4. Ketone bodies in renal function and diabetic kidney disease
- Mechchate H. , et al.
5. Factors Associated with Response to SGLT-2 Inhibitors and GLP-1 Receptor Agonists in Veterans with Type 2 Diabetes Mellitus †
- Arora G. , et al.
6. Fournier’s Gangrene in an HIV-Positive Patient Using a Sodium-Glucose Cotransporter-2 Inhibitor: A Case Report
- Yoon W. , et al.
7. Cardioprotective effectiveness of SGLT2 inhibitors in older diabetic women with early-stage breast cancer following anthracycline- and/or trastuzumab-based treatment
- Liu Y.S. , et al.
8. Effect of SY009, a novel SGLT1 inhibitor, on the plasma metabolome and bile acids in patients with type 2 diabetes mellitus
- Yang H. , et al.
9. Recent updates and the state of the art of renal biochemistry
- Ofori E.K. , et al.
10. Metabolic effects of pioglitazone and sodium-glucose cotransporter 2 inhibitors in familial partial lipodystrophy
- Soyaltin U. , et al.
11. Modern Challenges in Type 2 Diabetes: Balancing New Medications with Multifactorial Care
- Caturano A. , et al.
12. Effect of SGLT2 inhibitors on kidney function of type 2 diabetes patients during Ramadan: A systematic review
- Waheed M.A. , et al.
13. Antianginal effects of empagliflozin in patients with type 2 diabetes and refractory angina; a randomized, double-blind placebo-controlled trial (EMPT-ANGINA Trial)
- Mansouri M.H. , et al.
14. Incident infection risks depending on oral antidiabetic exposure in insulin-treated type 2 diabetes patients
- Park S. , et al.
16. SGLT2i and GLP-1 RA therapy in type 1 diabetes and reno-vascular outcomes: a real-world study
- Anson M. , et al.
17. Diabetic Kidney Disease: An Update
- Gupta S. , et al.
18. How Low Can You Go? Safety and Efficacy of Sodium-Glucose Cotransporter Inhibitors in Decreased Renal Function
- Barvian C.K. , et al.
19. Clinical and Safety Outcomes With GLP-1 Receptor Agonists and SGLT2 Inhibitors in Type 1 Diabetes: A Real-World Study
- Edwards K. , et al.
21. Patient-perceived benefits and risks of off-label use of SGLT2 inhibitors and GLP-1 receptor agonists in type 1 diabetes: a structured qualitative assessment
- Edwards K. , et al.
22. Metabolic effects of sodium-glucose co-transporter 2 inhibitor
- Kedyk A.V. , et al.
24. Prevalence of Bacterial Urinary Tract Infection Among Patients with Type 2 Diabetes Mellitus on Sodium-Glucose Cotransporter-2 Inhibitors: A Prospective Real-World Setting Study
- Ferwani P. , et al.
25. Sodium glucose Co-Transporter-2
- Mehta S. , et al.